A Mini-Review on Iron Chelating Agents as a Promising Therapeutic Target in Treatment of Leishmaniasis
Authors
Abstract:
There is a high prevalence of infections caused by Leishmania parasites and increasing rate of drug resistance. Lack of successful treatment with existing drugs calls for new therapeutic approaches. The main strategy in treatment of leishmaniasis is creating apoptosis and eliminating different forms of the parasite. So far, numerous drugs with specific mechanisms including 14-α-demethylase enzyme inhibition, inhibition of tubulin polymerization and cell division, radical formation, inhibiting the glycolytic and hydrolysis of fatty acids, and reducing the parasite's access to energy reserves such as ATP have been introduced. Moreover, different mineral compounds especially iron are needed for metabolism and survival of the parasite. This review article introduces iron-chelating compounds as a new therapeutic approach in treatment of leishmaniasis.
similar resources
Kinetoplast DNA: A Promising Drug Target for Treatment of Leishmaniasis
Leishmaniasis is a vector-borne zoonotic disease caused by various species of the genus Leishmania, (trypanosomatidae family) that is transmitted by phlebotomine sandflies. The disease can present in a range of clinical forms, including dermal lesions, metastasis mucocutaneous forms, and fatal visceral forms. In this non-systematic review, we aimed at introducing the role of kinetoplast DNA (kD...
full textApelin: A promising therapeutic target? (Part 1)
Apelin is a recently discovered bioactive peptide, known to be an endogenous high-affinity ligandfor the previously orphan G protein-coupled receptor APJ. Apelin/APJ as a novel signaling pathwayhas been shown to play many crucial roles in cardiovascular function, blood pressure regulation, fluidhomeostasis, feeding behavior, obesity, type 2 diabetes mellitus, adipoinsular axis regulation, cellp...
full textcannabinoids as a promising therapeutic approach for the treatment of glioblastoma multiforme: a literature review
gliobalstoma multiforme (gbm) or grade 4 astrocytoma is the most malignant form of primary brain tumor. treatment of glioblastoma is difficult despite of surgery, radiotherapy and chemotherapy. patients with glioblastoma survive for less than 12 months. considering to biology function of glioblastoma, researchers have recently offered new therapeutic approaches such as cannabinoid therapy for g...
full textIron stores in blood donors: A literature mini review
An increase in the frequency of blood donation among the donor population is liable to result in excessive iron loss and development of iron deficiency anemia. In the majority of blood banks, hemoglobin and/or hematocrit measurements are used as screening tests for the ability to donate blood even though iron stores may be depleted in donors with hemoglobin values above the arbitrarily defi...
full textHepcidin: A Promising Therapeutic Target for Iron Disorders
Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (e.g., iron-deficiency anemia and anemia of chronic diseases) and iron overload diseases, such as ...
full textP 86: CD166 as a Therapeutic Target in Autoimmune Diseases
About 3 decades ago CD6 identified as one of the first antigens expresses on the majority of T cells and a subset of B cells. CD6 regulates cellular adhesion migration across the endothelial and epithelial cells. In recent years researches indicate its role in pathogenesis of autoimmune diseases. Many researches have been done in recent years to block CD6 by CD6 mono clonal antibodies, IOR-T1 a...
full textMy Resources
Journal title
volume 30 issue 185
pages 173- 183
publication date 2020-05
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023